Skip to content

Category: Biotechnology

Stem cell manufacturing licence helps reduce Australia’s reliance on overseas bio-tech manufacturers

By API User

The Therapeutic Good Administration has granted Magellan Stem Cells a stem-cell manufacturing licence. The decision will help reduce Australia’s reliance on overseas manufacturing and encourage the commercialisation of innovative Australian cellular therapeutics, Magellan Stem Cells Chief Medical Officer, Associate Professor Julien Freitag said. “The licence from the federal regulator places Magellan as one of the … Continued

Corporate Presentation June 2025

By API User

  Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company’s strategy and progress on “Pioneering the Transformation of Ovarian Cancer Detection.”    The clinical unmet need for a screening solution for Ovarian Cancer is urgent.   Critically, no effective screening test currently exists, with the only way to definitively diagnose Ovarian Cancer … Continued

Australia’s New Green Alliance: How Pongamia Trees and PHA Are Powering a Cleaner Future

By API User

June 2025 – Australia As global industry races to decarbonise, an unlikely hero is emerging from the Australian landscape: the pongamia tree. Recently highlighted in Rio Tinto’s ambitious biofuels project, this native species is now at the centre of a broader movement, one that includes sustainable bioplastics, climate-resilient agriculture, and nature-based solutions to emissions reduction. … Continued

EARLY OVARIAN CANCER SCREENING BREAKTHROUGH

By API User

INOVIQ Limited (ASX: IIQ) is pleased to announce game-changing results from its EXO-OC™ ovarian cancer test presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2025 in Chicago. The Poster titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test is copied below. The test uses proprietary technology … Continued

ReNerve Limited Expands Surgical Product Portfolio Through Strategic Partnership with Berkeley Biologics (and Investor Webinar – 3 June 2025)

By API User

2 June 2025 – Melbourne, Australia | ReNerve Limited (ASX:RNV) has today announced a strategic partnership with US-based Berkeley Biologics, focused on developing and commercialising two new tissue-based product ranges, which will significantly expand its surgical offering in the peripheral nerve injury (PNI) space.  The collaboration between the organisations will see both product lines launched … Continued

ReNerve Secures Marketing Approval in Bahrain for Flagship NervAlign® Nerve Cuff(TM) Product

By API User

28 May 2025 – Sydney, Australia | ReNerve Limited has received marketing approval in Bahrain for its FDA-cleared NervAlign® Nerve Cuff™ product for peripheral nerve injuries (PNIs), marking its first regulatory milestone in the Middle East with its latest partner, Union MediScience B.S.C.  The approval will allow for the commercial rollout in Bahrain, and lays … Continued

OncoSil announces $8.7m capital raise to drive commercialisation

By API User

Highlights:  OncoSil Medical Limited (ASX:OSL) (OncoSil or Company) has received firm commitments for an $8.7m capital raise supported by existing and new shareholders, including strong support from several Australian institutional investors. Existing substantial shareholder, Pengana High Conviction Equities Fund was a cornerstone investor in the capital raise and will increase their holding in Oncosil following completion … Continued

CUREator + delivering up to $5M per Project Available for BioMedTech Startups Tackling Dementia and Cognitive Decline

By API User

22 May 2025:  The CUREator+ Dementia and Cognitive Decline Incubator Program, a partnership between Brandon BioCatalyst, ANDHealth, and Dementia Australia, has opened its second funding round.   Designed to support innovative solutions with the potential to improve the lives of Australians impacted by dementia, the program is seeking startups and companies focused on expanding treatment and wellbeing options for the … Continued